Novel Nucleoside
Transposon Therapeutics Acquired a Portfolio of Novel Nucleoside Analogs for Oncology To Enhance Development Pipeline
Transposon Therapeutics
PR-11-24-NI-119Nov 21, 2024
Clinical Trials
Transposon to Present Results from Phase 2 Study for the Treatment of ALS/FTD at the 7th Annual ALS ONE Research Symposium
Transposon Therapeutics
PR-10-24-NI-79Nov 07, 2024